High Dose Risankizumab for Psoriasis

Exclusion Criteria

• •Breastfeeding or pregnant women, or women who plan to become pregnant during study period
• •Participation in any other clinical trial
• •Active infection with HIV, hepatitis B virus, or hepatitis C virus
• •Active infection with tuberculosis or untreated latent tuberculosis
• •History of known active cancer, other than non-melanoma skin cancer or cervical carcinoma in situ, in the past 3 years
• •History of drug or alcohol abuse in the past 6 months, as per investigator's assessment
• •History of suicidal ideation or attempts in the past 6 months
• •Presence of any concurrent illness, which in the opinion of the investigator, would place the patient at unnecessary safety risk during the trial or interfere with completion of the trial
• •Treatment with topical medications for psoriasis in the past 2 weeks
• •Treatment with oral medications for psoriasis in the past 4 weeks
• •Phototherapy for psoriasis in the past 4 weeks
• •Any prior treatment with Risankizumab
• •Treatment with biologic medications for psoriasis (other than Risankizumab) in the past 4 months